Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Quiapeg Pharmaceuticals AB has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are split between distinct examiners, each working in a distinct art unit. This distribution means that every active matter is being handled by a different examiner in a different specialized group. The use of 2 pending office actions suggests that the company's technology spans multiple sub-sectors within the pharmaceutical field, which may require a diverse set of legal strategies to address the requirements of each department. Practitioners should note that the workload is not concentrated under a single person, which may lead to different prosecution timelines.
LIEB, JEANETTE M is the busiest examiner for this entity, managing 1 busiest examiner pending action. Although she is the busiest, her 1 busiest examiner pending action is matched by another examiner, as there are multiple distinct examiners in total. The distinct art units involved provide a diversified examination environment for the matters currently active for Quiapeg Pharmaceuticals AB. This structure allows for a broader range of feedback from the USPTO, as the 2 pending office actions are subject to the standards of different technical groups. Practitioners can use this lack of concentration to develop independent arguments for each case without the risk of a single examiner's perspective dominating the entire portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIEB, JEANETTE M | 1 | 79.8% | +17.4% |
| JARRELL, NOBLE E | 1 | 80.9% | +10.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18234142 | RELEASABLE CONJUGATES | JARRELL, NOBLE E | 46d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18444317 | RELEASABLE GLP-1 CONJUGATES | LIEB, JEANETTE M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18234142 | RELEASABLE CONJUGATES | JARRELL, NOBLE E | 46d |
| 18444317 | RELEASABLE GLP-1 CONJUGATES | LIEB, JEANETTE M | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18444317 | RELEASABLE GLP-1 CONJUGATES | LIEB, JEANETTE M | 1654 | §101DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18234142 | RELEASABLE CONJUGATES | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | 46d | Pending | Aug 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQuiapeg Pharmaceuticals AB has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jeanette M Lieb has the most, with 1 of Quiapeg Pharmaceuticals AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
